CTOs on the Move

Ra Medical

www.ramed.com

 
Advanced Excimer Laser-Based Vascular and Dermatological Therapies We are a medical device company leveraging our advanced excimer laser-based platform for use in the treatment of vascular and dermatological diseases. We believe our products enhance patients` quality of life by restoring blood-flow in arteries and clearing chronic skin conditions. We currently manufacture and market two lines of products: DABRA Catheter and Laser is cleared by the U.S. FDA as a tool for the minimally invasive endovascular treatment of vascular blockages resulting from lower extremity vascular disease, including peripheral artery disease (PAD) and critical limb ischemia (CLI). Pharos Excimer Laser is FDA ...
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million
  • www.ramed.com
  • 2070 Las Palmas Drive
    Carlsbad, CA USA 92011
  • Phone: 760.804.1648

Executives

Name Title Contact Details

Similar Companies

Biotab Nutraceuticals

Biotab Nutraceuticals is a Monrovia, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Amcare Medical Systems d/b/a Amcare Ambulance Service

Amcare Medical Systems d/b/a Amcare Ambulance Service is a Saint Albans, VT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Akros Pharma

Akros Pharma Inc. is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. Akros Pharma Inc. is based in Princeton, NJ. You can find more information on Akros Pharma Inc. at www.akrospharma.com

Covenant Care

Covenant Care is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. Covenant Care is based in Aliso Viejo, CA. You can find more information on Covenant Care at www.covenantcare.com

Alector

Alector is combining state-of-the-art antibody technology and recent discoveries in neuroimmunology and human genetics to develop novel therapeutics for Alzheimer`s disease, other forms of dementia, and mechanistically related neurodegenerative disorders. Alector`s strategy is to efficiently generate and validate antibody drugs with unique functional properties that engage key disease-altering targets. This approach is enabled by a strategic alliance with Adimab, the industry leader in discovery and optimization of antibody therapeutics. Alector is currently developing leads for 4 major targets and anticipates taking 2 of these through pre-clinical development and IND enabling studies within 24 months. Alector has incorporated a highly integrated and lean biotechnology structure with extensive outsourcing that supports core scientific and management teams.